Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma A/S (Nasdaq: ZEAL) announced the disclosure of transactions conducted by managerial personnel and their associates concerning the company's shares. This announcement is part of compliance with regulatory requirements and does not indicate any significant changes in management strategy or financial performance. Zealand Pharma, focused on innovative peptide-based medications, boasts a robust pipeline with over ten candidates in clinical development, two of which are already on the market. For further details, consult the attached documents.
- Robust pipeline with over 10 drug candidates in clinical development.
- Two drug candidates already on the market, boosting revenue potential.
- Partnerships with Boehringer Ingelheim and Alexion Pharmaceuticals, expanding market reach.
- None.
Company announcement – No. 6/ 2021
Copenhagen, DK and Boston, MA, U.S., February 8, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached files.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.
Zealand Pharma was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com
Attachments
FAQ
What transactions were disclosed by Zealand Pharma on February 8, 2021?
What is Zealand Pharma's focus in the biotechnology sector?
How many drug candidates does Zealand Pharma have in clinical development?
Which companies are Zealand Pharma partnered with?
What is the stock symbol for Zealand Pharma?
